<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4987">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02043002</url>
  </required_header>
  <id_info>
    <org_study_id>Thomas</org_study_id>
    <nct_id>NCT02043002</nct_id>
  </id_info>
  <brief_title>Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)</brief_title>
  <official_title>Early Changes in 18F-fluorodeoxyglucose Positron Emissions Tomography (18F-FDG-PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erlotinib, an anti-cancer agent targeting the epidermal growth factor receptor (EGFR), is an
      active treatment of patients with non-small cell lung cancer (NSCLC). Effect of treatment is
      primary seen in patients harboring a mutation in the EGFR. However, 10-15% of patients does
      not harbor a mutation but respond as well. Identifying these patients is a problem and
      methods are lacking.

      Studies have shown that an early 18F FDG-PET might can predict response and outcome in these
      patients, but further studies are needed to confirm these findings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>18F-FDG-PET evaluation</measure>
    <time_frame>Time to progression and latest april 2015 (up to 2 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Standardized Uptake Values (SUV) will be used as measurement of 18F-FDG uptake</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer Patients</condition>
  <arm_group>
    <arm_group_label>18F-FDG-PET scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An early evaluation 18F-FDG-PET scan after 7-10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>18F-FDG-PET scan</intervention_name>
    <arm_group_label>18F-FDG-PET scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung Cancer patients with non-small cell histology and stage IV disease

          -  candidate for erlotinib treatment as first/ second/ third line of treatment

        Exclusion Criteria:

          -  pregnancy

          -  severe dyspnoea
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Winther Larsen, MD</last_name>
    <email>anlarsen@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Meldgaard, Ph.D</last_name>
    <email>petemeld@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Jylland</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Winther Larsen, MD</last_name>
      <email>anlarsen@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Peter Meldgaard, Ph.D</last_name>
      <email>petemeld@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Meldgaard, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
